PHARMACY

FDA approves Aurobindo’s generic Dilantin

BY David Salazar

DAYTON N.J. — Aurobindo Pharma announced Thursday that its generic equivalent of Dilantin (extended phenytoin sodium) capsules in 100-mg dosage strength had been approved by the Food and Drug Administration.

The anti-epileptic medication is meant for treating and preventing seizures in patients during or after neurosurgery.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

DSN to present webinar on pharmacy provider regulations, data and verification

BY DSN STAFF

Pharmacy provider regulations continue to increase and, consequently, that means more scrutiny on information like Medicare and Medicaid provider enrollment and DEA registration. Having a process and system in place to maintain provider records, reduce compliance risk, and minimize payer reimbursement rejections will be absolutely critical for retail pharmacy stores and PBMs. 

To talk more about the massive challenges and opportunities facing community pharmacy,
Drug Store News will host a special webinar Tuesday, June 23, at 12 p.m. EST, presented by Health Market Science, a LexisNexis company.

Dan Schofield, head of product management, for Health Market Science, will explore three critical areas of discussion:

· The important regulations impacting retail pharmacy and PBM at the state and federal levels 
· The data necessary to manage the challenge of complying with these regulations 
· Technology and solutions that automate compliance at the point of sale 

A Q&A session will follow Schofield’s presentation. 

To register, click here

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

DSNTV: Leveraging technology to enable patient-facing pharmacy care

BY DSN STAFF

In the latest edition of DSNTV Executive Viewpoints, Doyle Jensen, EVP global business development for Innovation, talks to Drug Store News about the technology solutions available to help pharmacists spend more time delivering patient-facing care and less time filling prescriptions.

“The biggest impact is the labor cost,” Jensen explained of the company’s central fill offerings. “You’re able to get labor costs below 50 cents per prescription which in comparison to [filling in store] provides an ROI in anywhere from 12 to 24 to 36 months, and then you continue to leverage it for an addition seven, eight, nine years.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?